Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

Inclusion Criteria:

1. Must be able to understand and communicate with the investigator and comply with therequirements of the study

2. Chronic plaque-type psoriasis diagnosed for at least 6 months before screening

3. Stable plaque psoriasis

4. History of receipt of or candidate for therapy.

5. Moderate to severe psoriasis at screening and baseline

6. Must be willing and able to self-administer SC injections or have a caregiveravailable to administer injections

7. Male participants of childbearing potential must employ a highly effectivecontraceptive measure

8. Female participants must have a negative pregnancy test; are not planning to becomepregnant; and must not be lactating. Female participants must also agree to employ ahighly effective contraceptive measure.

Exclusion Criteria:

1. Forms of psoriasis other than chronic plaque-type

2. Drug-induced psoriasis.

3. Other skin conditions which would interfere with assessment of psoriasis

4. Medical conditions other than psoriasis for which systemic corticosteroids were usedin the last year prior to screening

5. Other inflammatory conditions other than psoriasis or psoriatic arthritis

6. Prior use of systemic tumor necrosis factor (TNF) inhibitors, or 2 or more non-TNFbiologic therapies

7. Ongoing use of prohibited psoriasis treatments

8. Ongoing use of other non-psoriasis prohibited treatments

9. All other prior non-psoriasis concomitant treatments must be on a stable dose for atleast 4 weeks

10. Laboratory abnormalities at screening deemed clinically significant by theinvestigator

11. Any condition or illness which in the opinion of the investigator or sponsor poses anunacceptable safety risk

12. History of latex allergy

13. History of or current signs or symptoms or diagnosis of a demyelinating disorder

14. History of or current Class III or IV New York Heart Association congestive heartfailure

15. Signs, symptoms, or diagnosis of lymphoproliferative disorders, lymphoma, leukemia,myeloproliferative disorders, or multiple myeloma

16. Current malignancy or history of any malignancy except adequately treated or excisednon metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma insitu; no more than 3 lifetime basal cell and squamous cell carcinomas permitted

17. Chronic infections, recurrent infections; recent infection to be evaluated

18. History of or presence of human immunodeficiency virus (HIV), or Hepatitis B (HBV) orC virus (HCV)

19. History of active tuberculosis (TB) or untreated or inadequately treated latent TB.

20. Exposure to an investigational product ≤30 days prior to enrollment or participationin another clinical study during the course of this study

21. Participant is a family member or employee of the investigator or site staff or studyteam